- What is Israel HealthCare Ventures' primary investment focus?
- Israel HealthCare Ventures is an Israeli life sciences venture fund, with approximately 75% of its portfolio in medical device companies and the remainder in pharmaceuticals and biotechnology.
- How many companies has Israel HealthCare Ventures invested in through its first two funds?
- Through IHCV I and IHCV II, Israel HealthCare Ventures has cumulatively invested approximately $135 million in 27 companies.
- Can you name a notable exit for Israel HealthCare Ventures?
- In October 2018, Israel HealthCare Ventures saw an exit with Gamida Cell, which went public on NASDAQ with a valuation of $210 million.
- What is Israel HealthCare Ventures' approach to investments?
- Israel HealthCare Ventures operates like a long-term investment company, adopting a hands-on approach by providing professional advice, ongoing management support, and an extensive network to its portfolio companies.
- What types of medical fields does Israel HealthCare Ventures' portfolio cover?
- Israel HealthCare Ventures' portfolio includes companies in cardiology, orthopedics, oncology, general surgery, gastroenterology, esthetics, and central nervous system, among others.
- Who is a key member of the Israel HealthCare Ventures team?
- Hadar Ron is a Co-founder & Managing Partner at Israel HealthCare Ventures.
- What was a significant acquisition exit for Israel HealthCare Ventures?
- In December 2009, Israel HealthCare Ventures had an exit when Optonol was acquired by Alcon for $150 million.
- What is one of Israel HealthCare Ventures' portfolio companies in the medical aesthetic device sector?
- Candela, a company focused on medical aesthetic devices, is one of Israel HealthCare Ventures' portfolio companies.